Effect of Onchocerciasis Elimination Measures on the Incidence of Epilepsy in Maridi, South Sudan

NCT05750043 | Completed FDA Drug

• 1 other identifier: Project Code AID 011898
• Study Type: observational
• Target: 17,000
• Locations: 1 country
• Sites: 1

Brief Summary

For the first time using a prospective design, a study confirms the results of previous retrospective studies, which found that strengthening onchocerciasis elimination efforts decreases the incidence of epilepsy, including nodding syndrome. Therefore, this study confirms the solid epidemiological link between onchocerciasis and epilepsy. This study also shows that a community-based "Slash and Clear" vector control method can effectively decrease blackfly biting rates and potentially decrease onchocerciasis transmission. Moreover, this study shows that epilepsy is a major cause of death in onchocerciasis endemic areas with high ongoing transmission.

Conditions

Onchocerciasis; Epilepsy

Outcome Measures

Primary Outcomes (1)

• epilepsy incidence

  Incidence of epilepsy including nodding syndrome

  4 years

Study Arms (1)

Population of selected villages in Maridi county

A total of 2,511 households containing 17,652 individuals were visited in 2018, and 2,254 households containing 14,402 individuals in 2022.

Drug: bi-annual CDTI

Interventions

bi-annual CDTI DRUG

bi-annual community directed treatment with ivermectin (CDTI) and community-based "slash and clear" vector control intervention

Also known as: "slash and clear" vector control intervention

Population of selected villages in Maridi county

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

The study was conducted in 44 villages from eight study areas in the central area of Maridi County: Hai-Gabat, Hai-Matara, Hai-Tarawa, Kazana-1, Kazana-2, Kwanga, Mudubai and Nagbaka.

You may qualify if:

• entire population of selected villages in Maridi County

Sponsors & Collaborators

• Universiteit Antwerpen: lead
• Amref Health Africa: collaborator

Study Sites (1)

Amref Health Africa

Juba, Central, 140, South Sudan

Location

MeSH Terms

Conditions

Onchocerciasis; Epilepsy

Condition Hierarchy (Ancestors)

Filariasis; Spirurida Infections; Secernentea Infections; Nematode Infections; Helminthiasis; Parasitic Diseases; Infections; Skin Diseases, Parasitic; Skin Diseases, Infectious; Skin Diseases; Skin and Connective Tissue Diseases; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases

Study Officials

• Jane Carter, MD

  Amref Health Africa

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: PROSPECTIVE
• Target Duration: 5 Years
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: February 19, 2023
• First Posted: March 1, 2023
• Study Start: March 1, 2018
• Primary Completion: January 31, 2023
• Study Completion: February 19, 2023
• Last Updated: November 30, 2023

Record last verified: 2023-11

Data Sharing

• IPD Sharing: Will not share

Locations

SO (1)